Margin resik BeiGene Oncology (ONC)

Tandha merek BeiGene Ltd. (ONC)

The sales margin of BeiGene Ltd demonstrates the efficiency of Asian development followed by the introduction of high-cost oncology drugs to Western markets, with the 13.90 metric serving as the target level. High scalability is driven by global distribution following the completion of costly trials. The company's organic growth relies on strategic partnerships with the world's largest pharma behemoths.

beigene.com (ONC) - Margin resik saka 04.07.2022 nganti 19.11.2026

Rincian metrik keuangan lan pasar BeiGene Ltd (ONC)

- rega saham lan prakiraan rega para ahli:
- rincian kapitalisasi pasar:
Pambiji fundamental perusahaan:BeiGene Corp - ONC
Produk asil prodhuksi BeiGene Oncology

The aggressive commercialization of BeiGene Ltd. (ONC) products under the leadership of John Euler in the US and China is clearly reflected in the net profit margin chart. This indicator is calculated as the ratio of net income to total revenue, measuring the actual earnings share of every dollar of sales, which allows investors to assess the business's operational efficiency and the risks of capital drawdown.

Pesaing wigati

Halozyme Corp (HALO) - Margin resik|Margin resik Revolution Medicines Inc (RVMD)|Margin resik Ascentage Pharma Group|Rentabilitas dodolan resik CGON (CG Oncology Corp)|Margin resik UroGen Pharma (URGN)|Margin dodolan resik Bicara Therapeutics (BCAX)|Margin dodolan resik PSNL (personalis.com)|Tingkat bathi resik ERAS|DCTH: Rentabilitas dodolan miturut bathi resik|YmAbs - Rentabilitas resik perusahaan|aurabiosciences.com (AURA) - Margin resik|Candel Therapeutics Inc. - Tingkat bathi resik|Margin resik Accuray Inc.|Margin resik SELLAS Life Sciences Group SLS|Margin dodolan resik ACTU|CTOR - Margin resik|Margin dodolan resik HURA (TuHURA Biosciences, Inc.)|Tingkat bathi resik TARA|FATE: Rentabilitas dodolan miturut bathi resik|WHWK (aadibio.com) - Rentabilitas dodolan resik|TCRX (TScan Therapeutics, Inc.) - Rentabilitas dodolan miturut bathi resik|Margin resik Champions Oncology Corp (CSBR)|XBIT (XBiotech Inc.) - Margin dodolan resik|CVM (CEL-SCI Corporation) - Rentabilitas resik perusahaan|Margin dodolan resik OSTX|Margin dodolan resik Radiopharm Theranostics Ltd (RADX)|Margin dodolan resik ARTV (Artiva Biotherapeutics)|Margin dodolan resik Adlai Nortye Ltd. ANL|Veru Inc - Margin dodolan resik|Margin dodolan perusahaan Tempest Therapeutics TPST|XLO: Margin dodolan resik|Enochian BioSciences (RENB) - Margin dodolan resik|Rentabilitas dodolan miturut bathi resik MURA|Kairos Pharma Ltd - Margin bathi resik|Margin dodolan resik OKUR|CytoMed Therapeutics Limited (GDTC) - Tingkat bathi miturut bathi resik|Margin dodolan resik CRIS (Curis, Inc.)|APLM: Rentabilitas dodolan resik|Tharimmune Corporation - Margin dodolan resik|ADVB: Margin resik|GNPX: Margin dodolan resik|CLDI (Calidi Biotherapeutics Inc.) - Margin resik|Margin resik Sunshine Biopharma, Inc.|Margin dodolan resik xeneticbio.com|Margin resik Salarius (SLRX)|Rentabilitas dodolan miturut bathi resik Purple Biotech PPBT|Margin resik American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Margin resik|Checkpoint Therapeutics Inc. - Margin dodolan resik|Tingkat bathi resik ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Rentabilitas dodolan miturut bathi resik|Ikena Oncology, Inc. - Tingkat bathi resik|Rentabilitas dodolan miturut bathi resik NTBL|VIRX: Tingkat bathi resik|Margin resik MorphoSys Corporation (MOR)|NAYA - Margin resik|Margin dodolan resik AAPGV (Ascentage)